Home Cart 0 Sign in  
X

[ CAS No. 24398-88-7 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 24398-88-7
Chemical Structure| 24398-88-7
Chemical Structure| 24398-88-7
Structure of 24398-88-7 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 24398-88-7 ]

Related Doc. of [ 24398-88-7 ]

Alternatived Products of [ 24398-88-7 ]

Product Details of [ 24398-88-7 ]

CAS No. :24398-88-7 MDL No. :MFCD00013529
Formula : C9H9BrO2 Boiling Point : -
Linear Structure Formula :- InChI Key :QAUASTLEZAPQTB-UHFFFAOYSA-N
M.W : 229.07 Pubchem ID :90488
Synonyms :

Calculated chemistry of [ 24398-88-7 ]

Physicochemical Properties

Num. heavy atoms : 12
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.22
Num. rotatable bonds : 3
Num. H-bond acceptors : 2.0
Num. H-bond donors : 0.0
Molar Refractivity : 50.23
TPSA : 26.3 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.2 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.19
Log Po/w (XLOGP3) : 3.52
Log Po/w (WLOGP) : 2.63
Log Po/w (MLOGP) : 2.97
Log Po/w (SILICOS-IT) : 2.71
Consensus Log Po/w : 2.8

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -3.65
Solubility : 0.0513 mg/ml ; 0.000224 mol/l
Class : Soluble
Log S (Ali) : -3.76
Solubility : 0.0402 mg/ml ; 0.000175 mol/l
Class : Soluble
Log S (SILICOS-IT) : -3.74
Solubility : 0.0419 mg/ml ; 0.000183 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 2.0
Synthetic accessibility : 1.62

Safety of [ 24398-88-7 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 24398-88-7 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 24398-88-7 ]
  • Downstream synthetic route of [ 24398-88-7 ]

[ 24398-88-7 ] Synthesis Path-Upstream   1~12

  • 1
  • [ 24398-88-7 ]
  • [ 141-78-6 ]
  • [ 21575-91-7 ]
YieldReaction ConditionsOperation in experiment
76.9%
Stage #1: With lithium hexamethyldisilazane In tetrahydrofuran at -78℃; for 0.25 h; Inert atmosphere
Stage #2: at -78℃; for 2 h; Inert atmosphere
[00457] To a stirred solution of 1.3 M LHMDS (25 mL, 32.7 mmol) in THF (10 mL) was added EtOAc (1.9 g, 21.8 mmol) at -78 °C under inert atmosphere. After being stirred for 15 min, ethyl- 3-bromo benzoate (5 g, 21.8 mmol) was added and stirring was continued for 2 h; progress of the reaction was monitored by TLC. The reaction was quenched with aq. NH4C1 (10 mL) and extracted with EtOAc (3 x 20 mL). The combined organic extracts were dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain the crude product. The crude material was purified by silica gel column chromatography eluting with 4percent EtOAc/Hexane to afford compound G (4.5 g, 76.9percent) as a mixture with its enolic form as a brown oil. 1H NMR (500 MHz, CDCls): δ 8.07 (s, 1H), 7.86 (d, J= 7.5 Hz, 1H), 7.73-7.69 (m, 1H), 7.37 (t, J= 7.0 Hz, 1H), 4.28-4.26 (m, 2H), 3.92 (s, 2H), 1.24 (t, J= 6.2 Hz, 3H). MS (ESI): m/z 298.8 [M-l].
Reference: [1] Patent: WO2015/191630, 2015, A1, . Location in patent: Paragraph 00457
[2] Bioorganic and Medicinal Chemistry, 2003, vol. 11, # 13, p. 2991 - 3013
  • 2
  • [ 24398-88-7 ]
  • [ 22726-00-7 ]
Reference: [1] Chemische Berichte, 1871, vol. 4, p. 707
  • 3
  • [ 24398-88-7 ]
  • [ 39115-96-3 ]
YieldReaction ConditionsOperation in experiment
89% With hydrazine hydrate In ethanol; waterReflux General procedure: Hydrazides (30–58) were synthesized by one pot conventionalmethod24 Benzoic acid or its derivative (10 mmol) was dissolvedin ethanol (20 mL). Sulfuric acid (3 N, 2 mL) was added and thereaction contents were refluxed for six hours. The reaction wasmonitored with TLC. After the completion of the reaction, the reactionmixture was neutralized by adding solid NaHCO3, and filteredto remove excess of NaHCO3. In the neutralized reaction mixture which contains ethyl ester, hydrazine monohydrate (1.5 mL,3 mmol) was added and refluxed for 3–6 h to complete the reaction.Ethanol and unreacted hydrazine were removed by distillationupto 1/3 volume. The reaction contents were cooled, filteredand recrystallized from methanol to obtain the desired hydrazidecrystals (see Supporting information).
86% With hydrazine In ethanol; water at 78℃; for 5 h; Embodiment 9; SYNTHESIS EXAMPLE 4; Synthesis Example 4 will specifically show a synthesis example of 2-(3-{N-[4-(carbazol-9-yl)phenyl]-N-phenylamino}phenyl)-5-phenyl-1,3,4-oxadiazole (abbreviation: mYGAO11) that is the oxadiazole derivative of the present invention represented by the structural formula (68) of Embodiment Mode 1.; Step 1: Synthesis of 2-(3-bromophenyl)-5-phenyl-1,3,4-oxadiazole (abbreviation: mO11Br); In Step 1, mO11Br was synthesized according to (i) to (iii) shown below.; (i) Synthesis of 3-bromobenzoylhydrazine; First, 10 g (44 mmol) of ethyl-3-bromobenzoate was put in a 200-mL three-neck flask, 50 mL of ethanol was added therein, and the mixture was stirred. Thereafter, 12 mL of hydrazine monohydrate was added therein, and the mixture was stirred at 78° C. for 5 hours so as to be reacted. After the reaction, water was added to the reaction solution, and a solid was precipitated. The precipitated solid was collected by suction filtration. The obtained solid was put in approximately 500 mL of water, washed, and again collected by suction filtration; thus, 8.1 g of a white solid that was an object was obtained (yield: 86percent).
86% With hydrazine In ethanol at 78℃; for 5 h; Synthesis Example 1 In the present Synthesis Example 1, a synthesis example of the oxadiazole derivative, 2-[3-(carbazol-9-yl)phenyl]-5-phenyl-1,3,4-oxadiazole (abbreviated designation: mCO11), of the present invention that is represented by the Structural Formula (G1) of Embodiment Mode 1 will be presented in concrete terms. <Step 1: Synthesis of 2-(3-bromophenyl)-5-phenyl-1,3,4-oxadiazole (abbreviated designation: mO11Br)> In the present Step 1, mO11Br was synthesized according to processes (i) to (iii) as given below. (i) Synthesis of 3-bromobenzoylhydrazine; After 10 grams (44 mmol) of ethyl-3-bromobenzoate were placed into a 200 mL, three-neck flask, 50 mL of ethanol was added thereto and the mixture was stirred; 12 mL of hydrazine monohydrate was added, this mixture was stirred at 78°C for 5 hours, and the contents of the flask were reacted together. After the reaction was completed, a solid was precipitated out with the addition of water to the reaction solution. The precipitate solid was removed by suction filtration. With the suction-filtered solid being placed into approximately 500 mL of water and washed and a solid removed by suction filtration, 8.1 grams of a white-colored solid, which was the objective of the synthesis process, were obtained at a yield of 86percent.
78% With hydrazine hydrate In ethanol for 10.25 h; Cooling with ice; Reflux 3-bromobenzoicacid ethyl ester 25 (1.5g, 6.6mmol) was dissolved in 15mL of ethanol, then under ice-cooling was slowly added dropwise with hydrazine hydrate (1.3g,26mmol), after the addition was complete, it was stirred at room temperaturefor 15min, then heated under reflux for 10h. After completion of the reaction, ethanol was removed by rotary evaporation, poured into water, extracted with ethyl acetate, the organic phase was dried and concentrated to give the desired product 26 (1.1g, 78percent), without purification into the next step.

Reference: [1] Bioorganic and Medicinal Chemistry, 2015, vol. 23, # 17, p. 6014 - 6024
[2] Patent: US2007/149784, 2007, A1, . Location in patent: Page/Page column 80-81
[3] Patent: EP1972625, 2008, A1, . Location in patent: Page/Page column 19-20
[4] Patent: CN105481765, 2016, A, . Location in patent: Paragraph 0090; 0091; 0092
[5] Journal of the Chinese Chemical Society (Peking), 1936, vol. 4, p. 69,72[6] Sci.Rep.Tsing Hua Univ.&lt;A&gt;, 1936, vol. 3, p. 555,558
[7] Phosphorus, Sulfur and Silicon and the Related Elements, 2006, vol. 181, # 9, p. 2079 - 2087
[8] Letters in Drug Design and Discovery, 2012, vol. 9, # 2, p. 135 - 139
[9] Archives of Pharmacal Research, 2014, vol. 37, # 7, p. 852 - 861
[10] Bioorganic and Medicinal Chemistry Letters, 2015, vol. 25, # 15, p. 3052 - 3056
[11] Medicinal Chemistry, 2015, vol. 11, # 8, p. 798 - 806
[12] European Journal of Medicinal Chemistry, 2016, vol. 120, p. 134 - 147
[13] Journal of the Brazilian Chemical Society, 2016, vol. 27, # 11, p. 1998 - 2010
[14] ChemMedChem, 2017, vol. 12, # 12, p. 972 - 985
[15] Chemical Biology and Drug Design, 2017, vol. 90, # 2, p. 236 - 243
[16] Organic Preparations and Procedures International, 2017, vol. 49, # 4, p. 370 - 376
[17] Bioorganic and Medicinal Chemistry, 2017, vol. 25, # 20, p. 5652 - 5661
[18] RSC Advances, 2018, vol. 8, # 12, p. 6306 - 6314
[19] Monatshefte fur Chemie, 2018, vol. 149, # 12, p. 2349 - 2358
  • 4
  • [ 24398-88-7 ]
  • [ 2463-16-3 ]
Reference: [1] Organic and Biomolecular Chemistry, 2015, vol. 13, # 9, p. 2541 - 2545
  • 5
  • [ 24398-88-7 ]
  • [ 58313-23-8 ]
Reference: [1] Tetrahedron Letters, 2002, vol. 43, # 20, p. 3645 - 3648
[2] Journal of the American Chemical Society, 2002, vol. 124, # 17, p. 4874 - 4880
  • 6
  • [ 24398-88-7 ]
  • [ 15852-73-0 ]
Reference: [1] Journal of Organic Chemistry, 1982, vol. 47, # 24, p. 4702 - 4708
[2] Tetrahedron Letters, 2010, vol. 51, # 46, p. 5973 - 5976
  • 7
  • [ 24398-88-7 ]
  • [ 7664-93-9 ]
  • [ 15852-73-0 ]
  • [ 95068-01-2 ]
Reference: [1] Chemische Berichte, 1904, vol. 37, p. 3695[2] Chem. Zentralbl., 1906, vol. 77, # I, p. 615
  • 8
  • [ 24398-88-7 ]
  • [ 30951-66-7 ]
Reference: [1] Journal of the American Chemical Society, 1957, vol. 79, p. 1906,1909
  • 9
  • [ 24398-88-7 ]
  • [ 676-58-4 ]
  • [ 30951-66-7 ]
Reference: [1] Chinese Chemical Letters, 2011, vol. 22, # 10, p. 1215 - 1218
  • 10
  • [ 24398-88-7 ]
  • [ 10601-99-7 ]
Reference: [1] Journal of Medicinal Chemistry, 2015, vol. 58, # 18, p. 7186 - 7194
  • 11
  • [ 24398-88-7 ]
  • [ 76008-73-6 ]
Reference: [1] Angewandte Chemie - International Edition, 2013, vol. 52, # 16, p. 4440 - 4444[2] Angew. Chem., 2013, vol. 125, # 16, p. 4536 - 4540,5
  • 12
  • [ 24398-88-7 ]
  • [ 215309-00-5 ]
Reference: [1] Tetrahedron, 1999, vol. 55, # 46, p. 13285 - 13300
[2] Tetrahedron, 1999, vol. 55, # 46, p. 13285 - 13300
[3] Tetrahedron, 1999, vol. 55, # 46, p. 13285 - 13300
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 24398-88-7 ]

Aryls

Chemical Structure| 67973-33-5

[ 67973-33-5 ]

Ethyl 3,5-dibromobenzoate

Similarity: 0.97

Chemical Structure| 5798-75-4

[ 5798-75-4 ]

Ethyl 4-bromobenzoate

Similarity: 0.97

Chemical Structure| 60469-88-7

[ 60469-88-7 ]

Ethyl 3,4-dibromobenzoate

Similarity: 0.95

Chemical Structure| 51760-21-5

[ 51760-21-5 ]

Dimethyl 5-bromoisophthalate

Similarity: 0.95

Chemical Structure| 618-89-3

[ 618-89-3 ]

Methyl 3-bromobenzoate

Similarity: 0.95

Bromides

Chemical Structure| 67973-33-5

[ 67973-33-5 ]

Ethyl 3,5-dibromobenzoate

Similarity: 0.97

Chemical Structure| 5798-75-4

[ 5798-75-4 ]

Ethyl 4-bromobenzoate

Similarity: 0.97

Chemical Structure| 60469-88-7

[ 60469-88-7 ]

Ethyl 3,4-dibromobenzoate

Similarity: 0.95

Chemical Structure| 51760-21-5

[ 51760-21-5 ]

Dimethyl 5-bromoisophthalate

Similarity: 0.95

Chemical Structure| 618-89-3

[ 618-89-3 ]

Methyl 3-bromobenzoate

Similarity: 0.95

Esters

Chemical Structure| 67973-33-5

[ 67973-33-5 ]

Ethyl 3,5-dibromobenzoate

Similarity: 0.97

Chemical Structure| 5798-75-4

[ 5798-75-4 ]

Ethyl 4-bromobenzoate

Similarity: 0.97

Chemical Structure| 60469-88-7

[ 60469-88-7 ]

Ethyl 3,4-dibromobenzoate

Similarity: 0.95

Chemical Structure| 51760-21-5

[ 51760-21-5 ]

Dimethyl 5-bromoisophthalate

Similarity: 0.95

Chemical Structure| 618-89-3

[ 618-89-3 ]

Methyl 3-bromobenzoate

Similarity: 0.95